Wołos-Kłosowicz, K.; Matuszewski, W.; Rutkowska, J.; Krankowska, K.; Bandurska-Stankiewicz, E.
Will GLP-1 Analogues and SGLT-2 Inhibitors Become New Game Changers for Diabetic Retinopathy? J. Clin. Med. 2022, 11, 6183.
https://doi.org/10.3390/jcm11206183
AMA Style
Wołos-Kłosowicz K, Matuszewski W, Rutkowska J, Krankowska K, Bandurska-Stankiewicz E.
Will GLP-1 Analogues and SGLT-2 Inhibitors Become New Game Changers for Diabetic Retinopathy? Journal of Clinical Medicine. 2022; 11(20):6183.
https://doi.org/10.3390/jcm11206183
Chicago/Turabian Style
Wołos-Kłosowicz, Katarzyna, Wojciech Matuszewski, Joanna Rutkowska, Katarzyna Krankowska, and Elżbieta Bandurska-Stankiewicz.
2022. "Will GLP-1 Analogues and SGLT-2 Inhibitors Become New Game Changers for Diabetic Retinopathy?" Journal of Clinical Medicine 11, no. 20: 6183.
https://doi.org/10.3390/jcm11206183
APA Style
Wołos-Kłosowicz, K., Matuszewski, W., Rutkowska, J., Krankowska, K., & Bandurska-Stankiewicz, E.
(2022). Will GLP-1 Analogues and SGLT-2 Inhibitors Become New Game Changers for Diabetic Retinopathy? Journal of Clinical Medicine, 11(20), 6183.
https://doi.org/10.3390/jcm11206183